Brief: AIM Immunotech Announces First Dose Level In Phase 1B/2 Study Of Ampligen And Imfinzi As A Combination Therapy
29/04/2024 14:01
April 29 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES FIRST DOSE LEVEL IS GENERALLY
WELL-TOLERATED IN PHASE 1B/2 STUDY OF AMPLIGEN AND IMFINZI AS A
COMBINATION THERAPY FOR LATE-STAGE PANCREATIC CANCER
Source text for Eikon: ID:nGNX3K0Vs3
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential